Hollister, Director of Sales and Marketing at PBI, explained: 'Multiple companies within these industries have now evaluated UST-produced nanoemulsions for their products. These UST demo/tolling partnerships are being designed to accelerate the trajectory of commercial proof of principle, production engagement, and finally conversion into long term processing relationships with a diverse universe of prospective partners spanning the pharmaceutical, nutraceutical, and personal care products industries. The Company is currently in discussions with potential business partners to fulfill certain strategic objectives, including: (i) accelerating demonstrations of its patented Ultra Shear Technologyв„ў ('USTв„ў') platform for processing nanoemulsions, and (ii) developing GMP-compliant toll manufacturing capacity to provide efficient and readily available fee-for-service production demands from small to medium scale manufacturers. (OTCQB:PBIO) ('PBI' or the 'Company'), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced it is advancing rapidly on plans to establish West and East Coast demonstration and tolling sites in the United States. SOUTH EASTON, MA / ACCESSWIRE / Septem/ Pressure BioSciences, Inc. Company Flooded with Opportunities to Demo Breakthrough UST Nanoemulsion Benefits and Serve Toll Production Demand in Pharmaceutical, Nutraceutical, and Personal Care Applications

Gmp requirements for cosmetics